ArticleMolecular biology reports2026
Reduced expression of SOCS1-5 and STAT5a genes in Parkinson's disease patients: evidence for dysregulated immune signaling.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, characterized by the loss of dopaminergic neurons in the substantia nigra. Recent studies suggest that immune dysregulation and alterations in signaling pathways play a key role in PD pathogenesis. The aim of this study was to investigate the expression of Signal transducer and activator of transcription (STAT) and Suppressor of cytokine signaling (SOCS) family genes in PD patients compared to control group.
methodsExpression of STAT and SOCS family genes in peripheral blood cells were measured using RT-qPCR technique and the results were statistically analyzed using R software.
resultsThere was no significant difference in the expression of STAT1, STAT3, STAT4, and STAT6 genes between the patient and control groups. However, the expression of SOCS1, SOCS2, SOCS3, SOCS5, and STAT5a genes in patients showed a significant decrease compared to the control group (p < 0.001, = 0.003, = 0.004, = 0.03 and = 0.007 respectively). Such decreases were significant between male subgroups for all these genes except SOCS5, for which neither male nor female subgroups showed a statistically significant difference. Regarding age, the expression of STAT1 and STAT6 genes decreased with increasing age (p = 0.046 and 0.04 respectively), while the decrease in STAT5a expression with increasing age was only seen in females (p = 0.001).
conclusionOur study demonstrated that the expression of STAT5a, SOCS1, SOCS2, SOCS3, and SOCS5 genes was significantly reduced in PD. Given that these molecules play a crucial role in anti-inflammatory pathways, their reduced expression may indicate defect in these pathways that contribute to the pathogenesis of PD. However, further studies are required to elucidate the exact effects of these changes.
Indexed as
Identifiers
42033629What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.